Pfizer, Dr Reddy's reach Effexor settlement; Lundbeck's Japanese partner wins Lexapro approval;

@FiercePharma:  Results of Avastin-Lucentis match-up due May 1. News | Follow @FiercePharma  

> Under a patent settlement with Pfizer, India's Dr. Reddy's Laboratories will be allowed to sell a generic version of Effexor XR, the Wyeth antidepressant drug, starting June 1. Report

> Cardinal Health has agreed to pay $8 million to resolve claims that it made payments to induce referral orders for its prescription drugs, according to a Department of Justice news release. News

> Lundbeck said its partner Mochida Pharmaceutical had obtained approval of antidepressant Lexapro in Japan, which would contribute positively to earnings next year. Story

> Baxter International reported stronger-than-expected quarterly earnings on higher sales of its medical products, and it raised its outlook for the full year. Item

> Amgen said it will begin paying a dividend this year amounting to about 20 percent of its adjusted net income, and increasing going forward. Article

> The trial of former GlaxoSmithKline lawyer Lauren Stevens gets under way this week, and federal prosecutors hope to force a GSK exec to testify, according to documents filed in federal court last week. News

> The FDA has approved the use of the Sanofi Pasteur vaccine Menactra in children as young as 9 months for the prevention of invasive meningococcal disease; the shot already is approved for use in people ages 2 through 55 years. FDA release

> The Irish government indemnified British drug company GlaxoSmithKline from liability from any side effects associated with the swine flu vaccine Pandemrix, which has recently been linked with the sleeping disorder narcolepsy. Story

> Alexion Pharmaceuticals' first quarter net income grew 25.4 percent as the drugmaker dug into its cash pile to fund acquisitions to rev up its pipeline of future drugs. Report

> Aurobindo Pharma won the FDA nod for its version of the Abbott Laboratories' Depakote drug, used to treat seizures and bipolar disorder. Item

> Pfizer Animal Health plans to discontinue its Promeris flea and tick preventive after a study linked the remedy to a rare autoimmune disease. News

Biotech News

 @FierceBiotech: VC report: Rounds get fatter as the number of deals shrinks. Story | Follow @FierceBiotech

 @JohnCFierce: Any price controls that are adopted at Medicare will be instantly applied by private payers; making this a top lobbying issue for biopharma. Follow @JohnCFierce

> Researchers eager to see pivotal Alzheimer's data on bapineuzumab. Story

> FDA's boceprevir review spotlights safety concerns. Report

> Confident of success, Vertex plans gangbuster rollout of telaprevir. Article

> Pfizer scrambles to reassure investors on blockbuster hopeful deaths. News 

Biotech IT News

> Layoffs target Genzyme Genetics IT workers, others. Story 

> PLoS highlights online DNA "encyclopedia." Report 

> Informatics firm Humedica raises $20M. Article 

> "Biopunk" illuminates world of bio-hackers. News 

> Study: EMRs could aid in disease research. Item 

> PatientsLikeMe study challenges prior ALS claims. Report 

Medical Device News

> Photologic goes into liquidation. Story 

> FDA OKs Boston Sci's ION stent system. Report 

> Gore: First patient enrolled in ascites study. News 

> GPO Novation signs Biotronik. Item 

> Jury awards St. Jude $2.3B in trade secrets case. Story 

> NMT's liquidation could mean end of libel case. News 

And Finally... Malaria cases in the UK have increased almost 30 percent since 2008, as people visiting family and friends in Asia and Africa didn't seek or adhere to medical advice to prevent the mosquito-borne disease. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.